12. SEGMENT INFORMATION (Details) - USD ($) |
3 Months Ended | 9 Months Ended | ||
|---|---|---|---|---|
Sep. 30, 2016 |
Sep. 30, 2015 |
Sep. 30, 2016 |
Sep. 30, 2015 |
|
| Product sales, net | $ 2,939,997 | $ 4,151,180 | $ 7,850,430 | $ 9,279,117 |
| Gross profit | 1,888,949 | 2,458,797 | 5,178,911 | 5,365,497 |
| Litigation settlement income | 0 | 756,714 | 0 | 756,714 |
| Selling, general and administrative | 3,072,441 | 3,888,898 | 9,147,411 | 10,716,814 |
| Research and development | 396,238 | 228,822 | 879,598 | 972,844 |
| Operating (loss) income | (1,579,730) | (902,209) | (4,848,098) | (5,567,447) |
| Consumer Products Segment [Member] | ||||
| Product sales, net | 2,939,997 | 4,151,180 | 7,850,431 | 9,279,117 |
| Gross profit | 1,888,949 | 2,458,797 | 5,178,911 | 5,365,497 |
| Litigation settlement income | 756,714 | 756,714 | ||
| Selling, general and administrative | 2,952,533 | 3,888,898 | 8,904,694 | 10,716,814 |
| Research and development | 292,738 | 228,822 | 658,817 | 972,844 |
| Operating (loss) income | (1,356,322) | (902,209) | (4,384,600) | (5,567,447) |
| Specialty Pharmaceutical Segment [Member] | ||||
| Product sales, net | 0 | 0 | 0 | 0 |
| Gross profit | 0 | 0 | 0 | 0 |
| Litigation settlement income | 0 | 0 | ||
| Selling, general and administrative | 119,908 | 0 | 242,717 | 0 |
| Research and development | 103,500 | 0 | 220,781 | 0 |
| Operating (loss) income | $ (223,408) | $ 0 | $ (463,498) | $ 0 |
| X | ||||||||||
- Definition Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of judgment or settlement awarded to (against) the entity in respect of litigation. No definition available.
|
| X | ||||||||||
- Definition The net result for the period of deducting operating expenses from operating revenues. No definition available.
|
| X | ||||||||||
- Definition The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Total revenue from sale of goods and services rendered during the reporting period, in the normal course of business, reduced by sales returns and allowances, and sales discounts. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|